• #25: Romvimza Receives FDA Approval for TGCT Treatment

  • 2025/02/21
  • 再生時間： 5 分
  • ポッドキャスト

#25: Romvimza Receives FDA Approval for TGCT Treatment

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Ono Pharmaceutical's Romvimza has been approved by the FDA for treating adult patients with symptomatic tenosynovial giant cell tumor (TGCT) when surgery is not a viable option. This provides another option for patients, in addition to Daiichi Sankyo’s Turalio, as both drugs inhibit the colony-stimulating factor 1 receptor (CSF1R). The approval was based on the MOTION trial, where Romvimza showed a 40% response rate at Week 25, compared to 0% for placebo, and also demonstrated improvements in range of motion, physical functioning, and pain. Ono acquired Romvimza through the purchase of Deciphera Pharmaceuticals. Romvimza offers a more convenient dosage of 30 mg twice weekly compared to Turalio's 250 mg twice daily. Notably, Turalio carries a black box warning and REMS program due to liver injury concerns, while Romvimza does not have either.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示

あらすじ・解説

Ono Pharmaceutical's Romvimza has been approved by the FDA for treating adult patients with symptomatic tenosynovial giant cell tumor (TGCT) when surgery is not a viable option. This provides another option for patients, in addition to Daiichi Sankyo’s Turalio, as both drugs inhibit the colony-stimulating factor 1 receptor (CSF1R). The approval was based on the MOTION trial, where Romvimza showed a 40% response rate at Week 25, compared to 0% for placebo, and also demonstrated improvements in range of motion, physical functioning, and pain. Ono acquired Romvimza through the purchase of Deciphera Pharmaceuticals. Romvimza offers a more convenient dosage of 30 mg twice weekly compared to Turalio's 250 mg twice daily. Notably, Turalio carries a black box warning and REMS program due to liver injury concerns, while Romvimza does not have either.

Hosted on Acast. See acast.com/privacy for more information.
続きを読む 一部表示

#25: Romvimza Receives FDA Approval for TGCT Treatmentに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。